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Abstract
Background: The World Health Organization (WHO) has recently recommended that antiretrovirals be initiated in
all individuals with CD4 counts of less than 350 cells/mm
3. For countries with resources too limited to expand care
to all such patients, it would be of value to able to identify and target populations at highest risk of HIV
progression. Renal disease has been identified as a risk factor for disease progression or death in some populations.
Methods: Times to meeting combination antiretroviral therapy (cART) initiation criteria (developing either a CD4
count < 200 cells/mm
3 or WHO stage 3 or 4 disease) and overall mortality were evaluated in cART-naïve, HIV-
infected Kenyan adults with CD4 cell counts ≥200/mm
3 and with WHO stage 1 or 2 disease. Cox proportional
hazard regression models were used to evaluate the associations between renal function and these endpoints.
Results: We analyzed data of 7383 subjects with a median follow-up time of 59 (interquartile range, 27-97) weeks.
In Cox regression analyses adjusted for age, sex, WHO disease stage, CD4 cell count and haemoglobin, estimated
creatinine clearance (CrCl) < 60 mL/min was significantly associated with shorter times to meeting cART initiation
criteria (HR 1.34; 95% CI, 1.23-1.52) and overall mortality (HR 1.73; 95% CI, 1.19-2.51) compared with CrCl ≥60 mL/min.
Estimated glomerular filtration rate (eGFR) < 60 mL/min/1.73 m
2 was associated with shorter times to meeting
cART initiation criteria (HR 1.39; 95% CI, 1.22-1.58), but not with overall mortality. CrCl and eGFR remained
associated with shorter times to cART initiation criteria, but neither was associated with mortality, in weight-
adjusted analyses.
Conclusions: In this large natural history study, reduced renal function was strongly associated with faster HIV
disease progression in adult Kenyans not initially meeting cART initiation criteria. As such, renal function
measurement in resource-limited settings may be an inexpensive method to identify those most in need of cART
to prevent progression to AIDS. The initial association between reduced CrCl, but not reduced eGFR, and greater
mortality was explained by the low weights in this population.
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Nearly 70% of all HIV-infected individuals globally
reside in sub-Saharan Africa, where access to healthcare
and, in particular, laboratory services is limited [1].
Despite significant strides in rolling out HIV treatment
services to the region, by December 2008, only 44% of
individuals requiring HIV treatment based on the 2006
World Health Organization (WHO) criteria (CD4 count
under 200 cells/mm
3, WHO stage 3 disease with a CD4
count under 350 cells/mm
3, or WHO stage 4 disease)
were receiving combination antiretroviral therapy
(cART) [2].
In the midst of the region’ss t r u g g l et op r o v i d ec A R T
to individuals meeting these conservative criteria for
treatment, WHO has recommended raising the CD4 cell
count criteria for treatment to 350 cells/mm
3,a sw e l la s
treating all individuals with tuberculosis [3]. Many coun-
tries are struggling with how to achieve this goal given
limited antiretroviral resources, and some are consider-
ing targeting specific populations, such as pregnant
women and individuals with tuberculosis, as part of the
initial phase of this expansion [personal communication:
National AIDS Control Program, Republic of Tanzania].
Ideally, countries with resources too limited to expand
care to all patients with CD4 counts of less than 350
cells/mm
3 would be able to identify and target other at-
risk populations.
Renal disease independently predicts progression to
AIDS and overall mortality in US urban women not
receiving cART [4,5]. In this study of urban American
women enrolled in the Women’s Interagency HIV Study
(WIHS) cohort, Szczech et al showed that dipstick pro-
teinuria, but not inverse creatinine, was significantly
associated with the development of a new AIDS-defining
illness [5]. However, Gardner et al [4] found that Amer-
ican women enrolled in the HIV Epidemiology Research
Study (HERS) before the availability of cART with either
a serum creatinine ≥1.4 mg/dL or proteinuria ≥2+ on
urine dipstick had a significantly greater risk of death.
Data related to the impact of renal disease on HIV pro-
gression and death in African cohorts has been limited
to one study from Zambia showing increased 90-day
mortality rates after cART initiation in patients with
reduced baseline renal function [6]. As such, data
related to the ability of renal disease to predict HIV pro-
gression and death in untreated HIV-infected African
populations is limited.
Although we acknowledge that HIV viral load in com-
bination with CD4 count is likely to be a better predica-
tor of progression than other measures, the availability
and cost of viral load testing can be prohibitive in
resource-limited settings. Given these constraints, we
c h o s et oe x p l o r et h ea s s o c i a tion between renal disease
and HIV disease progression and mortality in sub-
Saharan Africans. This study was designed to evaluate
this relationship between reduced renal function and
HIV disease progression to the 2006 WHO treatment
criteria [2], as well as death in a large population of
HIV-infected patients not requiring antiretrovirals at
enrolment into a care and treatment programme in wes-
tern Kenya.
Methods
Study design
We performed a retrospective analysis of data within the
electronic medical records of all patients enrolled into
the United States Agency for International Development
(USAID)-Academic Model Providing Access to Health-
care (AMPATH) programme from 6 January 2004
(when serum creatinine measurements were routinely
performed on all enrollees) until 31 March 2008. Follow
up was censored on 18 April 2008. This study was
approved by the research regulatory bodies of both the
Moi University and the Indiana University Schools of
Medicine.
Study site
AMPATH was initially created as a partnership between
Moi University School of Medicine, Moi Teaching and
Referral Hospital and a collaboration of North American
Medical Schools in November 2001 in order to provide
HIV care and treatment in western Kenya [7]. USAID
joined the partnership in 2003 when the programme
received funding through the US Presidential Emergency
Plan for AIDS Relief (PEPFAR). At the end of the study
period, the programme was providing HIV care for
52,798 adult patients, of whom 29,124 were on antire-
trovirals, at 18 sites throughout western Kenya.
Study cohort
We included only those individuals who were at least 18
years of age, had not previously received cART, had
complete enrolment data available for estimation of
renal function (age, sex, serum creatinine, weight) and
for other variables of interest (WHO disease stage, hae-
moglobin, CD4 cell count, eventual initiation of cART),
and did not meet USAID-AMPATH requirements for
immediate initiation of cART at presentation to care
(CD4 count under 200 cells/mm
3, WHO stage 3 disease
or WHO stage 4 disease) [8,9]. We also excluded
women who were pregnant at enrolment or who
became pregnant during follow up because dates of
pregnancy were not uniformly captured in the early
years of the AMPATH programme, so we could not
confidently attribute pregnancy versus an HIV-related
complication as the reason for cART initiation.
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At the initial visit, patients undergo a complete history, a
complete physical examination, a laboratory assessment
(complete blood count, CD4 cell count, Venereal Disease
Research Laboratory test (VDRL) and alanine amino-
transferase) and a chest x-ray. Serum creatinine is only
measured at the enrolment visit. Based on the results of
the symptom screen, physical exam and chest x-ray,
patients are assigned a WHO stage. Patients not meeting
WHO criteria for cART initiation were seen at one- to
three-month intervals depending on their co-morbidities.
During these visits, an interim history and a symptom-
directed exam were performed and CD4 cell counts were
obtained every six months. HIV-1 RNA levels were not
routinely measured in this cohort due to cost.
An outreach programme is utilized to locate patients
who fail to return for their scheduled appointments;
however, patients who have been initiated on cART are
preferentially traced. As such, there is both active sur-
veillance for death (through the outreach team) and pas-
sive surveillance (reports provided to the clinic from
family and friends). Data from all visits are recorded on
structured patient paper encounter forms and then
entered into the AMPATH Electronic Records System
by trained data entry clerks [10].
Statistical analyses
Enrolment renal function was estimated as both creati-
nine clearance (CrCl) using the Cockcroft-Gault equa-
tion [11] and estimated glomerular filtration rate (eGFR)
using the 4-variable Modification of Diet in Renal Dis-
ease (MDRD) equation [12]. The use of these particular
estimating equations and categorizations of CrCl and
eGFR were based on recommendations from the
National Kidney Foundation [13].
The primary endpoints for these analyses were: (1)
time to progression to AIDS, which we defined as meet-
ing WHO requirements for cART initiation (a compo-
site endpoint of developing either a CD4 count under
200 cells/mm
3 or developing WHO stage 3 or 4 dis-
ease): and (2) time to overall mortality. We specifically
chose to use times to meeting criteria for starting cART,
rather than actual times to starting cART, as treatment
may not have been initiated immediately when criteria
were met for a number of logistical and patient-related
reasons. Secondary endpoints included time to first CD4
count under 200 cells/mm
3 and time to development of
WHO stage 3 or 4 disease as separate outcomes as
opposed to a composite outcome.
Continuous variables are summarized by medians and
interquartile ranges (IQR); categorical variables are sum-
marized by frequencies and percentages. Comparisons of
continuous and categorical variables among groups with
different renal function parameters were performed with
Wilcoxon rank sum test and Chi-square test, respectively.
Cox proportional hazard regression models were used to
evaluate the associations between renal function and the
various endpoints after adjusting for other enrolment cov-
ariates that are known to be associated with either HIV
disease progression or HIV-related mortality, including
WHO stage (1 vs. 2), haemoglobin, CD4 cell count, age
and sex. All models were constructed with and without
cART initiation as a time-dependent variable.
We chose not to include weight in these initial models
as previous studies suggested that the inclusion of
weight in the Cockcroft-Gault formula, but not in the
simplified MDRD formula, led to significant differences
in renal function estimation in HIV-infected sub-
Saharan African patients [14]. After we found that there
were indeed appreciable differences in renal function
estimation between these two formulae and that CrCl,
but not eGFR, was significantly associated with overall
mortality, we then created weight-adjusted models to
determine if weight accounted for these differences in
predictive utility. The proportional hazard assumption
was tested by the method proposed by Lin et al [15].
All analyses were performed using SAS Version 9.2
(Cary, North Carolina). P values less than 0.05 were
considered statistically significant.
Results
Cohort characteristics
A total of 56,430 adults were enrolled into the USAID-
AMPATH programme during the study period. After
exclusions due to development of pregnancy during fol-
low up, not meeting study eligibility criteria, and lack of
complete enrolment data, 7383 remained for analysis
(Figure). This final analysis cohort of 7383 subjects was
similar to those excluded for lack of complete data. Spe-
cifically, the median (IQR) age and CD4 cell count were
35.5 (29.3-44.0) years and 385 (281-543) cells/mm
3,
respectively, for the analysis cohort, and 36.3 (29.0-42.5)
years and 400 (288-561) cells/mm
3, respectively, for
those excluded because of lack of complete data. The
percentages of male participants and those with WHO
stage 1 disease were 26.9% and 68.0% for the analysis
cohort, respectively, and 29.1% and 67.6% for the
excluded subjects, respectively.
The median (IQR) duration of follow up for the analy-
sis cohort was 59 (27-97) weeks. As shown in Figure 1,
14.2% of the analysis cohort developed CD4 counts of
less than 200 cells/mm
3, 14.0% developed WHO stage 3
or 4 disease, 24.1% developed either CD4 counts of less
than 200 cells/mm
3 or WHO stage 3 or 4 disease, and
1.8% died. Of note, the mortality rate in the 4259 sub-
jects who were excluded due to meeting cART initiation
criteria at enrolment was 1.4%. A total of 1962 (26.6%)
of the analysis cohort initiated cART during follow up.
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cART, with the median (IQR) time from cART initiation
to death being 19 (7-42) weeks.
Overall, 25.1% were lost to follow up during the study
period, which is similar to the lost-to-follow-up rates in
other large cohorts in sub-Saharan Africa [16]. Age, hae-
moglobin, WHO stage, proportions of men, and propor-
tions of those with CD4 cell counts under 350/mm
3 were
similar between those who were and were not lost to fol-
low up. However, there did appear to be differences in
56,430 new adult enrollees into the 
HIV programme from 2004 to 2008 
49,035 remaining  
11,642 excluded due to having enrolment 
WHO stage 3 or 4 disease or CD4 count 
<200cells/mm
3 
7395 women excluded due to pregnancy 
during follow up 
Outcomes during follow up 
1046 (14.2%) developed a 
CD4 count <200cells/mm
3 
 
1032 (14.0%) 
developed WHO stage 
3 or 4 disease 
131 (1.8%) 
died 
 
1851 (25.1%) were 
lost to follow up 
 
1776 (24.1%) developed either a 
CD4 count <200cells/mm
3 or  
WHO stage 3 or 4 disease 
30,010 excluded due to lack of enrolment 
data on haemoglobin, age, weight, serum 
creatinine, WHO stage or CD4 cell count 
19,025 remaining  
7383 remaining 
Figure 1 Selection and outcomes of AMPATH participants in these analyses.
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that 18.5% and 8.3% of those who were not lost to follow
up had enrolment CrCl < 60 mL/min and eGFR < 60
mL/min/1.73 m
2, respectively, whereas 24.9% and 12.4%
of those who were lost to follow up had enrolment CrCl
<6 0m L / m i na n de G F R<6 0m L / m i n / 1 . 7 3m
2, respec-
tively (both p < 0.05).
Table 1 shows the comparisons of enrolment charac-
teristics based on enrolment CrCl or eGFR. The propor-
tions of subjects with renal dysfunction differed based
on the estimating equation used. Greater age, having a
CD4 count of less than 350 cells/mm
3, and lower hae-
moglobin at enrolment were all significantly associated
with both a CrCl < 60 mL/min and eGFR < 60 mL/min/
1.73 m
2. Being female was associated with lower eGFR,
but not with lower CrCl, at enrolment. Having WHO
disease stage 1 (compared with stage 2) at enrolment
was associated with lower CrCl, but not with lower
eGFR. Lower enrolment weight was associated with
lower CrCl, but in contrast, lower weight was associated
with higher eGFR. Of note, the median (IQR) number
of days between visits for those with and without a CrCl
< 60 mL/min in our study cohort were similar at 28
(23-56) and 28 (23-53), respectively. The median (IQR)
numbers of days between visits for those with and with-
out an eGFR < 60 mL/min/1.73 m
2 were also similar at
28 (23-56) and 28 (25-56), respectively.
Associations between renal function and cART initiation
criteria
Overall, 30.7% and 15.0% of those who eventually met cri-
teria for cART initiation, respectively, had an enrolment
CrCl < 60 mL/min and an eGFR < 60 mL/min/1.73 m
2.
A ss h o w ni nT a b l e2( M o d e l1 ) ,o u rm u l t i v a r i a b l e
analyses showed that having an enrolment CrCl
< 60 mL/min, compared with an enrolment CrCl
≥60 mL/min, was significantly associated (HR, 1.34;
95% CI, 1.23-1.52; p < 0.0001) with shorter times to
meeting cART initiation criteria. Having an eGFR
< 60 mL/min/1.73 m
2 (Table 3, Model 1) was signifi-
cantly associated with shorter times to meeting cART
initiation criteria (HR, 1.39; 95% CI, 1.22-1.58; p <
0.0001). In both of these models, being male, having
WHO stage 2 disease, having a lower CD4 cell count
and having a lower haemoglobin level at enrolment
were also all independently associated (all p < 0.001)
with shorter times to meeting cART initiation criteria.
Age was not associated with the primary endpoint in
either model. The relationships between lower CrCl
or eGFR and times to meeting cART initiation criteria
were similar when adjusting for cART initiation.
Having a CrCl < 60 mL/min was also significantly
associated (p < 0.05) with developing a CD4 count of
less than 200 cells/mm
3. However, in the eGFR model
for this outcome, no category of reduced enrolment
eGFR was associated with shorter times to developing a
CD4 count of less than 200 cells/mm
3. In the multivari-
able model examining the associations between enrol-
ment CrCl and the outcome of developing WHO stage
3 or 4 disease, having a CrCl < 60 mL/min (p < 0.001)
was associated with shorter times to this outcome.
Having an enrolment eGFR < 60 mL/min/1.73 m
2 was
significantly associated (p < 0.001) with shorter times to
developing WHO stage 3 or 4 disease.
Table 1 Comparisons of the enrolment characteristics of the analysis cohort by creatinine clearance and estimated
glomerular filtration rate categories
Creatinine clearance (mL/min)
a Glomerular filtration rate
b (mL/min/1.73 m
2)
b
Characteristic
c Total
(n = 7383)
≥60
(n = 5890; 79.8%)
<6 0
(n = 1493; 20.2%)
P
value
≥60
(n = 6689;
90.6%)
<6 0
(n = 694;
9.4%)
P
value
Age, years 35.5 34.3 41.8 < 0.001 35.1 39.0 < 0.001
(29.3-44.0) (28.7-41.0) (33.8-49.4) (29.1-42.6) (32.1-46.5)
Female, n (%) 5399 (73.1) 4289 (72.8) 1110 (74.4) 0.24 4851 (72.5) 548 (79.0) < 0.001
CD4 cell count/mm
3, n (%)
>500 2263 (30.7) 1906 (32.4) 357 (23.9) < 0.001 2075 (31.0) 188 (27.1) 0.005
350-500 1993 (27.0) 1605 (27.2) 388 (26.0) 1821 (27.2) 172 (24.8)
< 350 3127 (42.4) 2379 (40.4) 748 (50.1) 2793 (41.8) 334 (48.1)
WHO stage 1, n (%) 5019 (68.0) 4054 (68.8) 965 (64.6) 0.002 4528 (67.7) 491 (70.8) 0.10
Haemoglobin, g/dL 12.6 12.6 12.2 < 0.001 12.6 12.3 0.003
(10.9-14.0) (11.0-14.0) (10.6-13.7) (11.0-14.0) (10.6-13.8)
Weight, kg 59.0 60.0 53.4 < 0.001 59.0 59.8 0.04
(52.0-65.5) (54.0-67.0) (48.0-60.0) (52.0-65.5) (53.0-67.0)
Serum creatinine, mg/dL 0.8 0.77 1.1 < 0.001 0.80 1.4 < 0.001
(0.7-1.0) (0.66-0.90) (1.0-1.3) (0.68-0.93) (1.2-1.6)
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adjustment for weight) with CrCl and eGFR treated as
continuous variables (data not shown). Lower continu-
ous CrCl was still significantly associated with shorter
times to meeting criteria for cART initiation, time to
CD4 cell count of less than 200/mm
3, and time to
WHO stage 3 or 4 disease (all p < 0.03). However,
eGFR as a continuous variable was not associated with
any of these outcomes.
Associations between renal function and overall mortality
A ss h o w ni nT a b l e4( M o d e l1 ) ,e n r o l m e n tC r C l<6 0
mL/min was significantly associated with shorter times
to overall mortality (HR, 1.73; 95% CI, 1.19-2.51; p <
0.01). In contrast, lower eGFR was not associated with
overall mortality (Table 5, Model 1). In both of these
models, greater age, being male, having WHO stage 2
disease and lower haemoglobin levels at enrolment were
all significantly associated with shorter times to overall
mortality (all p < 0.05). Lower enrolment CD4 cell
count and initiation of cART were not associated with
shorter times to death in either model. These associa-
tions were not appreciably altered in models that did
not adjust for cART initiation (data not shown). Lower
CrCl treated as a continuous variable was not associated
(p = 0.07) with time to overall mortality, whereas lower
eGFR as a continuous variable was again not associated
with overall mortality.
Influence of weight on the associations between renal
function estimates and outcomes
CrCl and eGFR renal function estimates differed in their
abilities to predict survival in our study cohort. Because
Table 3 Multivariable models showing the hazard ratios
for the associations between enrolment estimated
glomerular filtration rate and times to meeting criteria
for initiation of cART
a
Hazard ratios (95% confidence
intervals)
Enrolment characteristic Model 1 Model 2
b
Glomerular filtration rate
(mL/min/1.73 m
2)
c
≥60 (reference) 1.0 1.0
< 60 1.39 (1.22-1.58)
d 1.41 (1.23-1.61)
d
Age (per 10 year increase) 1.03 (0.98-1.08) 1.03 (0.98-1.08)
Male sex (compared with female
sex)
1.22 (1.08-1.36)
e 1.29 (1.14-1.45)
d
WHO stage 2 (compared with
stage 1)
1.35 (1.23-1.49)
d 1.30 (1.18-1.44)
d
CD4 cell count
(per 50 cells/mm
3 increase)
0.88 (0.87-0.90)
d 0.89 (0.87-0.90)
d
Haemoglobin (per 1 g/dL increase) 0.90 (0.88-0.92)
d 0.91 (0.89-0.93)
d
Weight (per 1 kg increase) 0.98 (0.98-0.99)
d
aCombination antiretroviral therapy, defined as development of either CD4
cell count < 200 cells/mm
3 or WHO disease stage 3 or 4.
bModel 1 adjusted for weight.
cEstimated using the 4-variable Modification of Diet in Renal Disease Equation.
dP < 0.0001.
eP < 0.001.
Table 2 Multivariable models showing the hazard ratios
for the associations between enrolment creatinine
clearance and times to meeting criteria for initiation of
cART
a
Hazard ratios (95% confidence
intervals)
Enrolment characteristic Model 1 Model 2
b
Creatinine clearance
c(mL/min)
≥60 (reference) 1.0 1.0
< 60 1.34 (1.23-1.52)
d 1.24 (1.11-1.39)
d
Age (per 10 year increase) 1.00 (0.95-1.05) 1.01 (0.96-1.07)
Male sex
(compared with female sex)
1.22 (1.09-1.37)
e 1.27 (1.13-1.42)
d
WHO stage 2
(compared with stage 1)
1.34 (1.22-1.48)
d 1.30 (1.18-1.43)
d
CD4 cell count
(per 50 cells/mm
3 increase)
0.88 (0.87-0.90)
d 0.88 (0.87-0.90)
d
Haemoglobin (per 1 g/dL increase) 0.90 (0.88-0.92)
d 0.91 (0.89-0.93)
d
Weight (per 1 kg increase) 0.99 (0.98-0.99)
d
aCombination antiretroviral therapy, defined as development of either CD4
cell count < 200 cells/mm
3 or WHO disease stage 3 or 4.
bModel 1 adjusted for weight.
cEstimated using the Cockcroft-Gault equation.
dP < 0.0001.
eP < 0.001.
Table 4 Multivariable models showing the hazard ratios
for the associations between enrolment creatinine
clearance and times to overall mortality
Hazard ratios (95% confidence
intervals)
Enrolment characteristic Model 1 Model 2
a
Creatinine clearance
b (mL/min)
≥60 (reference) 1.0 1.0
< 60 1.73 (1.19-2.51)
c 1.25 (0.84-1.86)
Age (per 10 year increase) 1.22 (1.02-1.45)
d 1.27 (1.07-1.51)
c
Male sex (compared with female
sex)
1.91 (1.29-2.81)
e 2.40 (1.61-3.59)
f
WHO stage 2 (compared with
stage 1)
1.54 (1.09-2.18)
c 1.37 (0.97-1.95)
CD4 cell count
(per 50 cells/mm
3 increase)
0.96 (0.91-1.01) 0.97 (0.91-1.02)
Haemoglobin (per 1 g/dL increase) 0.76 (0.72-0.81)
f 0.78 (0.73-0.83)
f
Initiation of antiretroviral therapy
(compared with no initiation)
1.36 (0.91-2.02) 1.35 (0.90-2.01)
Weight (per 1 kg increase) 0.95 (0.93-0.97)
f
aModel 1 adjusted for weight.
bEstimated using the Cockcroft-Gault equation.
cP < 0.01.
dP < 0.05.
eP < 0.001.
fP < 0.0001WE.
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outcomes in HIV-infected patients, we hypothesized
that the inclusion of weight in the Cockcroft-Gault
equation, but not in the simplified MDRD equation,
may explain these differences. To examine this more
closely, we then adjusted for weight in our models. Even
after this additional adjustment, CrCl was still signifi-
cantly associated, albeit less so, with shorter times to
meeting cART initiation criteria (Table 2, Model 2). In
other weight-adjusted models, lower CrCl remained sig-
nificantly associated with shorter times to developing
WHO stage 3 or 4 disease, but was no longer associated
with times to developing CD4 counts of less than 200
cells/mm
3 (data not shown). Lower eGFR, remained sig-
nificantly associated with shorter times to meeting
cART initiation criteria after adjustment for weight
(Table 3, Model 2). In the weight-adjusted survival mod-
els, neither lower CrCl (Table 4, Model 2) nor lower
eGFR (Table 5, Model 2) were associated with overall
mortality.
Discussion
To our knowledge, the current study is the largest ana-
lysis to date investigating the natural progression of HIV
disease in sub-Saharan African adults not initially
receiving antiretroviral therapy. As such, we could inves-
tigate with high confidence multiple predictors of both
eventual need for cART and overall mortality.
Our primary goal was to evaluate the utility of renal
function to predict HIV-related outcomes. We found
that lower renal function, defined either as estimated
CrCl < 60 mL/min or as estimated eGFR < 60 mL/min/
1.73 m
2, at enrolment was independently associated
with an increased risk of HIV disease progression. Our
results differ from the only other study to assess renal
a b n o r m a l i t i e sa sp r e d i c t o r sf o rA I D Sp r o g r e s s i o ni n
patients not receiving cART [5].
In analyses of the Women’s Interagency HIV Study
(WIHS) cohort, Szczech et al [5] found that dipstick
proteinuria, but not inverse creatinine, was significantly
associated with the development of a new AIDS-defining
illness. Several reasons may explain the differences in
results. The WIHS cohort included only women,
whereas our study included both men and women. Dif-
ferences in diet and environmental conditions may also
have contributed to the discrepant results. The defini-
tions of renal function also differed between our ana-
lyses. Szczech et al used inverse creatinine as a
continuous predictor variable, while we used categorical
definitions of both estimated creatinine clearances and
glomerular filtration rates. Perhaps most importantly,
the WIHS cohort analysis could adjust for multiple
other potentially confounding variables, including HIV-1
RNA levels, proteinuria, albuminuria and presence of
other co-morbidities (hepatitis C co-infection, diabetes,
hypertension), which we did not have available in our
study cohort.
We did not find in weight-adjusted analyses that renal
function was associated with overall mortality. Again,
our results conflict somewhat with those from the
WIHS analyses, in which inverse creatinine predicted
mortality in women who did not receive cART. In addi-
tion, Gardner et al [4] found that American women
enrolled in the HIV Epidemiology Research Study
(HERS) before the availability of cART with either a
serum creatinine ≥1.4 mg/dL or proteinuria ≥2+ on
urine dipstick had a significantly greater risk of death.
The differences between our study and the HERS
study may have occurred for similar reasons as noted
already between our African cohort and the WIHS
cohort. However, in follow-up analyses from the WIHS
cohort, Estrella et al [17] found that having an eGFR <
60 mL/min/1.73 m
2 prior to initiation of cART was
associated with higher mortality. In addition, a large
Zambian study of nearly 26,000 patients initiating cART
[6] found that 90-day mortality rates after cART initia-
tion were significantly higher in patients with reduced
baseline renal function. The lack of association between
reduced renal function and mortality in those initiating
cART in our study may have occurred due to a relative
lack of power since only 1946 subjects eventually
received cART in our cohort. In our experience, the
mortality rates in the proportion of patients who are
lost to follow up are significantly higher than those
observed among patients retained in care; as such, high
rates of loss to follow up may have impacted this out-
come [18,19].
The mechanisms by which reduced renal function may
lead to faster HIV disease progression are not completely
clear. The most likely explanation is that the observed
relationships may be confounded by the lack of adjust-
ment for HIV-1 RNA levels and increased systemic
inflammation, both of which are related to HIV disease
progression and renal function [20-23]. Additional stu-
dies that incorporate these HIV disease progression mar-
kers are needed to better understand the relationships
between renal dysfunction and outcomes in both
resource-limited and resource-rich environments.
In patients with low muscle mass, low serum creati-
nine values may more likely reflect reduced creatinine
generation even in the face of renal function impair-
ment. Thus, the use of serum creatinine alone to esti-
mate renal function would not be appropriate for the
current study cohort. Given the presence of patients
with protein malnutrition and HIV wasting in our
cohort (both etiologies of muscle wasting), we chose to
use estimated renal function using the two most com-
mon equations currently in practice, namely the
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equation, which incorporate variables that should adjust
for variability in muscle mass. As such, both equations
include not only serum creatinine, but also age and sex.
The Cockcroft-Gault equation, in contrast with the 4-
v a r i a b l eM D R De q u a t i o n ,a l s oi n c l u d e sw e i g h t .O u r
results demonstrate that the specific inclusion of weight
in the Cockcroft-Gault equation greatly influenced the
prevalence estimates of reduced renal function estimates
in this Kenyan population not yet receiving cART.
Our results corroborate those from another HIV-
infected African cohort [14] in which the prevalence of
renal dysfunction was much greater when using the
Cockcroft-Gault equation compared with the simplified
MDRD equation. In addition, adjustment for weight in
the CrCl prediction models reduced the association
between reduced CrCl and HIV disease progression and
completely negated the relationship between lower CrCl
and mortality in our study. The importance of weight in
our analyses should not be surprising given that lower
weight has long been known to be associated with
decreased survival in those infected with HIV [24,25]. In
addition, it should also be noted that the lack of associa-
tions between renal function and outcomes in our mod-
els using CrCl and eGFR as continuous variables suggest
that the renal function may only be associated with out-
comes once a critically low threshold is met and not at
higher values.
Several limitations should be acknowledged. As men-
tioned earlier, the retrospective design relied on using
existing data, so several other potential predictors of
clinical outcomes, such as HIV-1 viral loads, proteinuria,
C-reactive protein, metabolic abnormalities and viral
hepatitis co-infection status, could not be studied.
Because serum creatinine was not calibrated to the
MDRD reference laboratory, bias may have occurred
and would limit comparisons with other populations
[26]. We acknowledge that missing data, including
serum creatinine values, in a substantial number of the
USAID-AMPATH enrollees, may limit generalizability.
However, the very large sample size of the analysis
cohort and its similarity to the excluded patients greatly
mitigates this limitation. Also, the results of this study
may not extend to those groups who were excluded
from these analyses, namely women who became preg-
nant during the study period. However, we believe our
results may be generalizable to other sub-Saharan Afri-
can cohorts.
In our study, approximately 20% had CrCl < 60 mL/
min and 9.4% had stage 3 chronic kidney disease, as
defined by the National Kidney Foundation as an esti-
mated eGFR < 60 mL/min/1.73 m
2. These proportions
are similar to published reports of the frequency of
renal dysfunction in patients in Zambia, Uganda, and
Zimbabwe [6,14]. In addition, our cumulative probability
of 22% for meeting cART initiation criteria over the first
year is similar to a previous Ugandan study [27] investi-
gating the natural progression of HIV infection to
WHO stage 4 disease (26%) for those who had either
stage 1 or 2 disease at initial diagnosis. The relatively
short follow-up period may have also limited our ability
to find significant associations between reduced renal
function and mortality in several of our models. Finally,
we acknowledge that neither the Cockcroft-Gault equa-
tion to estimate CrCl nor the simplified MDRD equa-
tion to estimate eGFR has been fully validated in an
antiretroviral-naïve HIV-infected population. Thus the
accuracy of these estimating equations to reflect true
renal function in sub-Saharan African patients is not
known.
Conclusions
In conclusion, we have shown that reduced renal func-
tion, estimated as either lower CrCl or lower GFR, in
HIV-infected Kenyans not initially meeting cART elig-
ibility criteria was associated with faster HIV disease
progression. However, renal dysfunction was not asso-
ciated with overall mortality in HIV-infected Kenyans.
The relatively inexpensive cost for estimating renal func-
tion in resource-limited HIV care programmes may be
justified in the context of providing additive utility in
identifying those who will have faster HIV disease pro-
gression and thus require cART more urgently.
Availability of cART is expanding in Kenya, but this
availability is not yet sufficient to treat all patients who
would otherwise meet current treatment initiation cri-
teria used in resource-rich settings. Thus, identifying
even a relatively small proportion of patients (i.e., those
with lower renal function) with CD4 counts of more
than 200/mm
3 and WHO disease stage 1 or 2 would
still be beneficial in identifying those who most need
cART. Because the simplified MDRD equation to esti-
mate GFR remains independently associated with meet-
ing cART intiation criteria, even when accounting for
weight, age, sex and serum creatinine, this equation may
be preferable to the Cockcroft-Gault equation as a
means to measure renal dysfunction in the context of
predicting HIV disease progression. Additional research
is needed to understand the mechanisms underlying the
associations between renal disease and progression to
AIDS.
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